Drug AMG 410 for metastatic tumors with KRAS mutations (20240031)

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
[20240031] A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
Principal Investigator
Headshot of John Strickler
Professor of Medicine
Protocol Number
IRB: PRO00118236
NCT: NCT07094113
Phase
Phase I
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL
Participate